Jelnu

Tamsulosin Hydrochloride and Dutasteride, the active ingredients in Jelnu, are an alpha‑1 adrenergic antagonist and a 5‑alpha‑reductase inhibitor presented as an oral tablet formulation for oral use. They are indicated for the management of benign prostatic hyperplasia in adult men.

GNH USA supplies Jelnu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Customers benefit from reliable supply chains and responsive technical support throughout the ordering process.

Jelnu combines tamsulosin and dutasteride to address benign prostatic hyperplasia and related lower urinary tract symptoms.

- Benign prostatic hyperplasia (BPH): Improves urinary flow and reduces urgency, frequency, and nocturia. - Prostatic enlargement: Decreases prostate volume over time, relieving urethral obstruction. - Lower urinary tract symptoms (LUTS) associated with BPH: Alleviates bladder outlet obstruction and enhances quality of life.

Jelnu may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Dizziness: Light‑headedness, especially after the first dose. - Abnormal ejaculation: Decreased volume or retrograde ejaculation. - Headache: Mild to moderate intensity. - Nasal congestion: Stuffy or runny nose.

Serious or Rare Side Effects: - Priapism: Persistent, painful erection requiring immediate medical attention. - Severe hypotension: Marked drop in blood pressure leading to fainting. - Allergic reactions: Rash, itching, or swelling of the face and throat.

When prescribing Jelnu, clinicians should consider several safety measures to minimize risk.

- Monitor blood pressure: Assess for orthostatic changes, particularly after initiation. - Assess PSA levels: Obtain baseline prostate‑specific antigen before therapy. - Avoid use in severe hepatic impairment: Dose adjustment may be necessary. - Caution in cataract surgery patients: Increased risk of intra‑operative floppy iris syndrome. - Store at ambient temperature: Keep in the original container, protect from moisture and light.

Jelnu can interact with other medicines; awareness of major and moderate interactions helps ensure safe use.

Major Interactions (Avoid): - Finasteride: Concurrent use may increase sexual side‑effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole): May raise dutasteride plasma concentrations. - Other alpha‑blockers (e.g., doxazosin): Additive hypotensive effect. - Warfarin: Potential enhancement of anticoagulant activity.

Moderate Interactions (Monitor Closely): - Diuretics: May potentiate orthostatic hypotension. - Antihypertensives: Blood pressure should be regularly monitored.